2018 American Transplant Congress » Poster Session B: Kidney Immunosuppression: Induction Therapy

Date: Sunday, June 3, 2018

Time: 6:00pm-7:00pm

Location: Hall 4EF

Session Type: Poster Session

Meeting: 2018 American Transplant Congress

6:00pm-7:00pm: A Comparison of Alemtuzumab versus Antithymocyte Globulin Induction in High-Risk, Non-Sensitized Renal Transplant Recipients

S. Patel, A. Lichvar, E. Benedetti, P. West-Thielke.

6:00pm-7:00pm: A Meta-Analysis for Induction Therapy of Kidney Transplantation: Comparison of Antithymocyte Globulin and Interleukin 2 Receptor Antagonist

G. Chen, Z. Wu, C. Wang, X. Liu, C. Wang, L. Chen.

6:00pm-7:00pm: A Protocol for the Management of Alemtuzumab Induced Leukopenia in Kidney Transplant Recipients

S. Hammad, B. Ravichandran, M. Crist, B. Masters.

6:00pm-7:00pm: Adjusted Body Weight Dosing of Rabbit Antithymocyte Globulin in Obese Renal Transplant Recipients Preserves Excellent Clinical Outcomes at 3 Years and Improves the Value of Care

J. Dann, A. Agarwal, M. Bradley, W. Ally.

6:00pm-7:00pm: Age Stratified Efficacy and Safety Outcomes of Induction Immunosuppression in Renal Transplantation

D. McKimmy,¹ H. Kuzaro,² S. Sakya,³ K. Belfield,¹ E. Cohen.¹

6:00pm-7:00pm: Alemtuzumab Induction is Effective and Safe in Elderly Kidney Transplant Recipients

A. Toledo, K. Szempruch, P. Serrano, K. Andreoni, T. Kozlowski.

6:00pm-7:00pm: Anti-Thymocyte Globulin vs. Alemtuzumab: A Comparison of Long-Term Outcomes among Renal Transplant Recipients

E. Loncharic, A. Dodson, K. Gutierrez.

6:00pm-7:00pm: Basiliximab Induction in HIV-Positive Renal Transplant Recipients Compared to an HIV-Negative Cohort

J. Schulte,¹ C. Richardson,¹ V. Stosor,² K. Cunningham,¹ C. D'Agostino,¹ C. Kane.¹

6:00pm-7:00pm: Basiliximab Induction in Simultaneous Liver-Kidney Transplant

C. Song, X. Luo, L. Pote, S. Strout, D. Segev, N. Desai, A. Gurakar, F. Navqi, J. Garonzik Wang.

6:00pm-7:00pm: Comparison of De Novo Rapamune versus Everolimus Maintenance Immunosuppression; an Interim Analysis

R. Pelletier, A. Rajab, M. Henry, G. Bumgardner.

6:00pm-7:00pm: Cytomegalovirus Prophylaxis Following Alemtuzumab Induction in High Risk Renal Transplant Recipients Experiencing Delayed Graft Function

S. Freedman, B. Ravichandran, B. Masters, E. Heil, K. Saharia, J. Bromberg, A. Haririan, T. Sparkes.

6:00pm-7:00pm: Developing a Rationale for an Appropriate Immunosuppressive Regimen in Lung vs Kidney Transplant Recipients: Effects of Induction Therapy

P. Martin-Moreno,^1,2 H. Shin,^1,3 H. Goldberg,⁴ A. Chandraker.¹

6:00pm-7:00pm: Differences in Rejection and Clinical Outcomes in Obese versus Non-Obese Renal Transplant Recipients Receiving Basiliximab Induction Immunosuppression

J. Benken,¹ C. Kane,² A. Lichvar,¹ E. Benedetti.¹

6:00pm-7:00pm: Early Allograft Biopsy in Kidney Transplant Recipients with DGF – Call for an Individualized Approach

A. Vijay, L. Barrison, M. Cooper, S. Ghasemian.

6:00pm-7:00pm: Effect of rATG on Monocytic Myeloid-Derived Suppressor Cells and Its Associated Mechanisms in Kidney Transplantation Recipients

Y. Jiang, X. Zhang.

6:00pm-7:00pm: Higher Rates of Rejection in HIV-Infected Kidney Transplant Recipients on Ritonavir-Boosted Protease Inhibitors–Three-Year Follow Up

B. Rollins, S. Farouk, G. DeBoccardo, S. Lerner, M. Rana, S. Huprikar, L. Miko, V. Delaney, S. Florman, R. Shapiro.

6:00pm-7:00pm: Immunosuppression and the Risk of Dementia among Older Kidney Transplant Recipients

M. McAdams DeMarco,¹ C. Haugen,¹ S. Bae,¹ K. Lentine,² D. Segev.¹

6:00pm-7:00pm: Impact of Immunogenicity on Kidney Allograft Survival in Patients Treated with Induction Therapy

D. Bekbolsynov, B. Mierzejewska, M. Rees, J. Ortiz, O. Ekwenna, S. Stepkowski.

6:00pm-7:00pm: Impact of Single Nucleotide Polymorphisms on P450 Oxidoreductase and Peroxisome Proliferator-Activated Receptor alpha on Tacrolimus Pharmacokinetics in Renal Transplant Recipients

Z. Wang, Z. Han, J. Tao, H. Chen, S. Li, R. Tan, M. Gu.

6:00pm-7:00pm: Individualized Immunosuppression through Risk-Stratification in Renal Transplantation Preserves Excellent Outcomes at Three Years

J. Dann, A. Agarwal, M. Bradley, J. Geyston, W. Ally.

6:00pm-7:00pm: Induction Type and Outcomes in HLA-DR Mismatch Kidney Transplantation

K. Sureshkumar, S. Hussain, B. Chopra.

6:00pm-7:00pm: Lack of Efficacy of Eculizumab for Prevention of Delayed Graft Function (DGF) in Deceased Donor Kidney Transplant Recipients

P. Heeger,¹ E. Akalin,² M. Baweja,¹ R. Bloom,³ S. Florman,¹ B. Haydel,¹ D. Hricik,⁴ S. Kulkarni,⁵ A. Mehrotra,¹ A. Patel,⁶ E. Poggio,⁷ L. Ratner,⁸ S. Schröppel,¹ R. Shapiro.¹

6:00pm-7:00pm: Once-Daily versus Twice-Daily Tacrolimus in De Novo Living Kidney Transplantation Patients: A Multicenter, Parallel Group, Open-Label, 5-Year Randomized Noninferiority Trial

Y. Kakuta,¹ M. Okumi,¹ K. Unagami,² M. Furusawa,¹ H. Ishida,¹ K. Tanabe.¹

6:00pm-7:00pm: Optimal Anti-Thymocyte Globulin Dose for Induction Immunosuppression in Kidney Transplantation

A. Mitrokhin, J. Goldman, B. Trivedi, V. Vidyasagar, N. Vadivel, M. Hart.

6:00pm-7:00pm: Optimal Protocol for ABO Incompatible Kidney Transplantations: Analysis of 400 Cases in a Single Center Experience

H. Kwon, Y. Kim, J. Choi, S. Shin, J. Jung, M. Cho, J. Kim, D. Han.

6:00pm-7:00pm: Outcomes Associated with Rabbit Anti-Thymocyte Globulin Induction According to Mg/Kg of Total Body Weight in Kidney Transplant Recipients

A. Brueckner, A. Logan, L. Bowman.

6:00pm-7:00pm: Pharmacogenetics of CYP3A4, CYP3A5, CYP2C8 and CYP2C19 and Their Influence on Tacrolimus Pharmacokinetics in Renal Transplant Recipients

Z. Wang, Z. Han, J. Tao, H. Chen, L. Sun, R. Tan, M. Gu.

6:00pm-7:00pm: Preemptive Rituximab in Focal and Segmental Glomerulosclerosis Patients at Risk for Recurrence after Transplantation

P. Auñon,¹ N. Polanco,¹ M. Perez,² E. Rodrigo,³ A. Sancho,⁴ J. Pascual,² A. Andres,¹ M. Praga.¹

6:00pm-7:00pm: Risk of Bacteremia According to Transplant Induction Immunosuppression Regimen

E. Misch, S. Kelley, G. Leverson, B. Astor, D. Kaufman.

6:00pm-7:00pm: Safety and Efficacy of Real-World Use of Everolimus for Kidney Transplant Patients: Post-Marketing Surveillance in Japan

H. Harada,¹ Y. Watarai,² J. Uchida,³ O. Kamisawa.⁴

6:00pm-7:00pm: Single Reduced Dose Thymoglobuline as Induction in Kidney Retransplant

K. Linhares-Silva, M. Cristelli, L. Viana, C. Felipe, H. Proença, R. de Marco, J. Medina-Pestana, H. Tedesco Silva J�nior.

6:00pm-7:00pm: Successful Transplantation in a Sensitized Patient Allergic to Commercially Available Antibody Induction Agents

K. Venkatachalam, A. Malone.

6:00pm-7:00pm: Survey of Rabbit Anti-Thymocyte Globulin Usage for Kidney Transplant Induction Therapy in the United States

K. Foster,¹ A. Dodson,² K. Gutierrez.²

6:00pm-7:00pm: The Efficacy and Safety of Rituximab as Induction Therapy in Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials

X. Wang,¹ J. Chen,² X. Tu,² Y. Qiu,¹ T. Song,¹ T. Lin.¹

6:00pm-7:00pm: The Influence of Rabbit Antithymocyte Globulin (rATG) Dose on the Incidence of CMV Infection in Kidney Transplant Recipients Receiving No Pharmacological Prophylaxis. A Propensity Score Matched Cohort Analysis

M. Ivani de Paula,^1,2 S. Bae,¹ J. Garonzik-Wang,¹ C. Felipe,² M. Cristelli,² A. Massie,^1,3 J. Medina-Pestana,² D. Segev,^1,3 H. Tedesco Silva J�nior.²

6:00pm-7:00pm: Thymoglobulin Dose and Effect on Short-Term Kidney Transplant Outcomes

P. Sood, W. Christine, R. Mehta, A. Tevar, C. Puttarajappa, K. Schonder, K. Shimko, S. Hariharan.

« View all sessions from the 2018 American Transplant Congress